2Y30 Stock Overview
Provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Bionano Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.39 |
| 52 Week High | US$28.00 |
| 52 Week Low | US$4.39 |
| Beta | 2.19 |
| 1 Month Change | 0% |
| 3 Month Change | -16.62% |
| 1 Year Change | -80.92% |
| 3 Year Change | 13.70% |
| 5 Year Change | -93.07% |
| Change since IPO | -93.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2Y30 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | -0.4% |
| 1Y | -80.9% | -12.0% | 4.2% |
Return vs Industry: 2Y30 underperformed the German Life Sciences industry which returned -22.5% over the past year.
Return vs Market: 2Y30 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 2Y30 volatility | |
|---|---|
| 2Y30 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2Y30's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2Y30's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 405 | Robert Holmlin | www.bionano.com |
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.
Bionano Genomics, Inc. Fundamentals Summary
| 2Y30 fundamental statistics | |
|---|---|
| Market cap | €49.26m |
| Earnings (TTM) | -€138.65m |
| Revenue (TTM) | €29.82m |
1.6x
P/S Ratio-0.3x
P/E RatioIs 2Y30 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2Y30 income statement (TTM) | |
|---|---|
| Revenue | US$31.51m |
| Cost of Revenue | US$23.52m |
| Gross Profit | US$7.99m |
| Other Expenses | US$154.51m |
| Earnings | -US$146.52m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.88 |
| Gross Margin | 25.35% |
| Net Profit Margin | -464.96% |
| Debt/Equity Ratio | 0% |
How did 2Y30 perform over the long term?
See historical performance and comparison